anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Aprepitant
Trial phase: Phase 2
ATC code: A04AD12
SMILES: C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: 125mg/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
Eligibility criteria:
Inclusion Criteria:

Males or females from 18-70 years of age
Meets DSM IV criteria for current cannabis dependence
Seeking research-based outpatient treatment for cannabis dependence that involves daily oral medication
Smoked MJ daily at least 25 days per month during the 90 days prior to randomization
Current cannabis use verified by a positive urine test > 50 ng/ml
At least a 2-year history of regular MJ use
Willing and able to give informed consent

Exclusion Criteria:

Abstinent from cannabis more than 2 days at the time of randomization
Currently meets DSM IV criteria for dependence on substances, or has urine drug screen positive for substances, other than cannabis or nicotine
Meets DSM IV criteria for a major AXIS I disorder other than cannabis and nicotine dependence,
Active suicidal ideation
Significant medical disorders that will increase potential risk or interfere with study participation,
Females who are pregnant, nursing or who are sexually active with child-bearing potential and refuse to use a double-barrier method of birth control during the study and for up to 4 weeks after study termination
Ongoing treatment with medications that may affect study outcomes,
Use of CYP3A4 strong inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) and CYP3A4 moderate inhibitors (e.g., diltiazem) within the 2 week period prior the study drug administration or within 5 half-lives of the respective medication, whichever is longer, until study conclusion.
Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study drug administration until study conclusion.
Ongoing treatment with medications that are primarily metabolized by CYP3A4 and may have increased plasma concentrations when co-administered with aprepitant, such as pimozide, terfenadine, astemizole or cisapride or corticosteroids, as well as benzodiazepines including midazolam, alprazolam, and triazolam.
Ongoing treatment with medications that are primarily metabolized by CYP2C9 (e.g., warfarin, tolbutamide).
Use of drugs (e.g., rifampin, carbamazepine, phenytoin) or herbal supplements (e.g., St John's wort) that induce CYP3A4 activity and may result in reduced plasma concentrations of aprepitant and decreased efficacy of aprepitant.
Inability to understand and/or comply with the provisions of the protocol and consent form.
Intervention: Lidocaine
Trial phase: Not Applicable
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 90
Group description: Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared with 2% lidocaine gel before use in the examination.

2% lidocaine gel: 2% lidocaine gel will be used to coat the urethral catheters and cotton tipped swab before use during the examination.
Eligibility criteria:
Inclusion Criteria:

Women 18 years of age or older
Scheduled to undergo multichannel urodynamic study
Able to give informed consent
Able to read and write in English or Spanish

Exclusion Criteria:

Any contraindication to multichannel urodynamic study
Allergy to water based lubricant or lidocaine
Any active pelvic or lower urinary tract infection
Intervention: Acetylcysteine
Trial phase: Phase 2
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 100
Group description: Patients receiving NAC (N-acetylcysteine)

N-acetylcysteine: N-acetylcysteine (NAC), 1200 mg Oral route 2 doses
Eligibility criteria:
Inclusion Criteria:

Must have at least 2 nevi (each >6 mm diameter) not clinically suspicious for melanoma that can be biopsied.
Must be able to receive informed consent and sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

The patient is a minor (< 18 years old).
The patient cannot speak/understand English or Spanish. (NOTE: A Spanish consent form and certified interpreter can be made available if needed)
The patient is pregnant. (NOTE: All female patients who have not had a hysterectomy and are not post-menopausal (i.e. post-menopausal for 1 year and not of child-bearing potential) will have a urine pregnancy test.)
The patient is a prisoner, critically or mentally ill, or otherwise incapacitated or considered vulnerable.
The patient has history of allergic reaction to NAC.
The patient has history of severe asthma.
The patient has been taking NAC or any other oral antioxidant.
The patient has recent history (i.e., 3 months) of sunless tanning (tanning bed) or extensive sunburn.
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 146
Group description: dexamethasone 10 mg administration 1 hour before surgery
Eligibility criteria:
Inclusion Criteria:

Diagnosis of primary osteoarthritis, knee
Scheduled for elective total knee arthroplasty
Signed written informed consent

Exclusion Criteria:

Refusing participate
Contraindication to regional anesthesia
Severe impairment of bowel motility
administration of other antiemetic drug within 24hours before surgery
systemic steroid within 24hours before surgery
history of cardiovascular & respiratory disease
renal & hepatic failure
Intervention: Pioglitazone
Trial phase: Phase 4
ATC code: A10BD05 | A10BD06 | A10BD09 | A10BD12 | A10BG03
SMILES: CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Pioglitazone: Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
Eligibility criteria:
Inclusion Criteria:

Age 18-70 years
Fasting insulin >12 μU/mL and/or serum glucose between 140-200 mg/dl after 75 g 2hr oral glucose tolerance test
Central fat deposition or Peripheral fat atrophy
Fasting glucose ≤126 mg/dL
BMI ≥18 and ≤35 kg/m2
CD4 cell count ≥100 cells/mm3
Stable antiretroviral regimen ≥12 weeks and HIV RNA <1000 copies

Exclusion Criteria:

Diabetes mellitus
Cardiac pacemaker or metal implant
Liver enzymes >2.5x upper normal limit
Alkaline phosphatase or prothrombin time >2x upper normal limit
Serum creatinine >1.4 mg/dL
History of congestive heart failure
Hemoglobin <8 g/dL
Alcohol abuse
Pregnancy
History of lactic acidosis
Use of steroids
Acute infection within last one month
History of bladder cancer
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Subjects will receive Ozurdex injections and will be monitored for macular edema.

Ozurdex: Ozurdex .7 mg injected into the treated eye
Eligibility criteria:
Inclusion Criteria:

Patients who are undergoing pars plana vitrectomy for:

Epiretinal membrane/vitreomacular traction or
Diabetic macular edema
Patients with macular edema as measured by OCT (at least 250 um central subfoveal thickness)
Informed consent requirements: All study subjects must agree to participate in the study and provide written informed consent, which will be written in English.
Age between 18-85 years old

Exclusion Criteria:

Age < 18 years or > 85 years

History of macular edema due to diseases other than those in the inclusion criteria in the study eye

History of active inflammatory eye disease (uveitis) (within 3 months)
History of ocular malignancy and/or ocular/orbital irradiation
History of recent retinal vein occlusion (within 6 months)
History of neovascular age-related macular degeneration or choroidal neovascular membrane [
History of juxtafoveal telangiectasia
History of Coat's disease
History central serous choroidoretinopathy
History of previous infectious retinitis (toxoplasmosis, acute retinal necrosis, tuberculosis, etc)
Patients with a history of intraocular infection in the study eye (i.e. viral retinitis, endophthalmitis)
Patients who are cognitively impaired or those who are unable to provide informed written consent
Patients with a history of glaucoma in the study eye (defined as increased cup to disc ratio with associated nerve damage. Patients with ocular hypertension controlled by topical glaucoma drops (maximum 3) will not be excluded).
Patient with recent intravitreal injections of steroids or anti-VEGF medications in the study eye (within past 4 weeks).
Patients with recent periocular steroid injection (within past 4 weeks) in the study eye
Patients on topical NSAIDS drops (patient will be eligible if they discontinue use of topical NSAIDs at time of study enrollment) in the study eye
Intervention: Insulin lispro (5.97 MG)
Trial phase: Phase 4
SMILES: CC(C)CC(NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(Cc1cnc[nH]1)NC(=O)C(CO)NC(=O)CNC(=O)C(CS)NC(=O)C(CC(C)C)NC(=O)C(Cc1cnc[nH]1)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc1ccccc1)C(C)C)C(C)C)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CS)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc1ccccc1)C(=O)NC(Cc1ccccc1)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(C(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(C(=O)O)C(C)O)C(C)O)C(C)C.CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC(CS)C(=O)NC(CS)C(=O)NC(C(=O)NC(CO)C(=O)NC(C(=O)NC(CS)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(N)=O)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CS)C(=O)NC(CC(N)=O)C(=O)O)C(C)CC)C(C)O)C(C)C
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 20
Group description: 3 doses of Mix 50/50 at mealtime

Insulin LISPRO : Humalog® Mix50/50™ [50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)], three times daily at mealtime. Dose determined by blood glucose history.
Eligibility criteria:
Inclusion Criteria:

Pregnant and at least 13 weeks gestation
Diagnosed with gestational diabetes mellitus
Failed diet therapy

Exclusion Criteria:

<18 years old or over 45 years old
urine dipstick >2+ protein
blood pressure >140/80 mmHg
hematocrit <30%
refusal to take insulin
inability to understand instructions or to consent to participate.
Intervention: Humalog
Trial phase: Phase 4
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)NC(CCCCN)C(=O)N3CCCC3C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 20
Group description: 3 injections of Humalog(r) daily with meals; 3 injections of Humulin N (r) daily on rising, mid-afternoon, and at bedtime

Insulin, Long-Acting and Insulin LISPRO : Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
Eligibility criteria:
Inclusion Criteria:

Pregnant and at least 13 weeks gestation
Diagnosed with gestational diabetes mellitus
Failed diet therapy

Exclusion Criteria:

<18 years old or over 45 years old
urine dipstick >2+ protein
blood pressure >140/80 mmHg
hematocrit <30%
refusal to take insulin
inability to understand instructions or to consent to participate.
Intervention: Ganirelix
Trial phase: Phase 4
ATC code: H01CC01
SMILES: CC/N=C(\NCC)NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN/C(=N/CC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Study subjects will receive 7 days of pre-treatment with a GnRH antagonist (Delayed Start) before standard ovarian stimulation with FSH/LH.

Ganirelix acetate: Subjects will receive 7 days of pre-treatment with the GnRH antagonist
Eligibility criteria:
Inclusion Criteria:

Antral Follicle Count (AFC) less than or equal to 4 as measured by transvaginal ultrasound (TVUS), or
Cancellation of a prior IVF cycle due to poor ovarian response.
Patients will receive an antagonist stimulation protocol for IVF, or IVF with Intracytoplasmic Sperm Injection (ICSI).

Exclusion Criteria:

Severe male factor infertility requiring surgical intervention to obtain sperm
Major uterine abnormality,
Preimplantation genetic diagnostic (PGD) testing,
Planned cycles without embryo transfer (for example, freeze-all, donor, or surrogate cycles).
Intervention: Ganirelix
Trial phase: Phase 4
ATC code: H01CC01
SMILES: CC/N=C(\NCC)NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN/C(=N/CC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Ovarian stimulation with standard antagonist protocols (no delay).

Ganirelix acetate: Subjects will receive 7 days of pre-treatment with the GnRH antagonist
Eligibility criteria:
Inclusion Criteria:

Antral Follicle Count (AFC) less than or equal to 4 as measured by transvaginal ultrasound (TVUS), or
Cancellation of a prior IVF cycle due to poor ovarian response.
Patients will receive an antagonist stimulation protocol for IVF, or IVF with Intracytoplasmic Sperm Injection (ICSI).

Exclusion Criteria:

Severe male factor infertility requiring surgical intervention to obtain sperm
Major uterine abnormality,
Preimplantation genetic diagnostic (PGD) testing,
Planned cycles without embryo transfer (for example, freeze-all, donor, or surrogate cycles).
Intervention: Tamoxifen
Trial phase: Phase 2
ATC code: L02BA01
SMILES: CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 52
Group description: All patients enrolled in the study.

Tamoxifen: All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.

Breast cancer surgery: Breast cancer surgery
Eligibility criteria:
Inclusion Criteria:

Age > 18 years old
Diagnosed with hormone receptor positive invasive breast cancer (estrogen receptor (ER) or progesterone receptor (PR) or both >1%) by core needle biopsy
Clinical American Joint Committee on Cancer (AJCC) 7th edition Stage 1 or 2
Candidate for surgical therapy
Eastern Cooperative Oncology Group (ECOG) performance status 0,1, or 2
No chemotherapy or endocrine therapy for breast cancer in last 5 years
Paraffin fixed core needle tissue block, or biopsy punch available for central analysis for proliferative markers
Not pregnant or lactating and practicing adequate birth control if premenopausal
Able and willing to provide informed consent

Exclusion Criteria:

Prior personal history of uterine cancer
Prior personal history of stroke or deep vein thrombosis (DVT)
Current therapy with strong CYP2D6 inhibitors The following medications should not be administered with tamoxifen (21 day treatment period) and will need to be stopped for the designated period of time prior to starting the study tamoxifen.

No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage 0, I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years

Fluoxetine - should be discontinued 30 days prior to starting tamoxifen Paroxetine - should be discontinued 5 days prior to starting tamoxifen Sertraline - should be discontinued 5 days prior to starting tamoxifen Bupropion - should be discontinued 5 days prior to starting tamoxifen

Concurrent coumarin-type anticoagulation therapy
Any other contraindications to tamoxifen therapy
Intervention: Lurasidone Hydrochloride
Trial phase: Phase 3
SMILES: Cl.O=C1C2C3CCC(C3)C2C(=O)N1CC1CCCCC1CN1CCN(c2nsc3ccccc23)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 282
Group description: SM-13496 40 mg or 80 mg was orally administered for 26 weeks to the participants who completed the prior study (D1001056), in which, SM-13496 (40 mg or 80 mg) or placebo was administered for 6 weeks.
Eligibility criteria:
Inclusion Criteria:

Patients who are considered by the investigator eligible for the present study with no significant safety concerns
Patients who are fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study

Exclusion Criteria:

Patients who are planning pregnancy for the expected duration of the study
Patients who are otherwise considered ineligible for the study by the investigator
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: Single shot sciatic nerve blocks will be performed by resident trainees supervised by faculty. Bupivacaine 0.625% with epinephrine 1:300,000 will be injected incrementally in 3-ml aliquots to a total volume of 0.4 ml/kg (minimum, 20 ml; maximum, 35 ml).

Bupivacaine: Bupivacaine 0.625% with epinephrine 1:300,000
Eligibility criteria:
Inclusion Criteria:

all patients ( ≥18 and ≤ 80) who are scheduled to undergo elective scheduled foot surgery and agreed to receive a sciatic nerve catheter as a part of their postoperative pain management. this study.

Exclusion Criteria:

history of hemostatic abnormalities
chronic pain syndrome
a foot deformity restricting normal foot movement
severe liver or renal disease
a preexisting neurologic disorder
patient refusal to participate
the presence of language barrier that prohibits proper communication with patient.
Intervention: Ropivacaine
Trial phase: Phase 4
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: Continuous sciatic nerve block catheters will be performed using an insulated needle connected to the negative lead of a constant current nerve stimulator. The catheter will be advanced under ultrasound guidance. A test dose of 1.5% lidocaine with epinephrine will be injected to confirm catheter placement. All subjects will receive a portable pump that will infuse 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr. The subjects will follow standard protocol discharge instructions in regards to removing the catheter themselves.

Ropivacaine: 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
Eligibility criteria:
Inclusion Criteria:

all patients ( ≥18 and ≤ 80) who are scheduled to undergo elective scheduled foot surgery and agreed to receive a sciatic nerve catheter as a part of their postoperative pain management. this study.

Exclusion Criteria:

history of hemostatic abnormalities
chronic pain syndrome
a foot deformity restricting normal foot movement
severe liver or renal disease
a preexisting neurologic disorder
patient refusal to participate
the presence of language barrier that prohibits proper communication with patient.
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine and perineural dexamethasone 8mg/2mL ,and 50mL IV normal saline infusion
Eligibility criteria:
Inclusion Criteria:

ASA 1-3 patients who are presenting for foot and ankle surgery and are candidates for a single injection sciatic nerve block to provide postoperative analgesia.
Surgery confined to the foot and ankle.
Patients aged 18-70 years.

Exclusion Criteria:

ASA Classification of 4 or higher.
Pre-existing neuropathy
Coagulopathy
Infection at the site
Diabetes
Non-English speaking or reading patients
Systemic use of corticosteroids within 6 months of surgery
Chronic opioid use
Pregnancy
Large (>3cm) skin incision around the medial aspect of the foot
Any other contra-indication to regional anesthesia
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline/2mL and IV dexamethsone 8mg in 50mL infusion
Eligibility criteria:
Inclusion Criteria:

ASA 1-3 patients who are presenting for foot and ankle surgery and are candidates for a single injection sciatic nerve block to provide postoperative analgesia.
Surgery confined to the foot and ankle.
Patients aged 18-70 years.

Exclusion Criteria:

ASA Classification of 4 or higher.
Pre-existing neuropathy
Coagulopathy
Infection at the site
Diabetes
Non-English speaking or reading patients
Systemic use of corticosteroids within 6 months of surgery
Chronic opioid use
Pregnancy
Large (>3cm) skin incision around the medial aspect of the foot
Any other contra-indication to regional anesthesia